Furthermore, some existing drugs targeting component conditions of MetS, including metformin, simvastatin and exenatide, may upregulate skeletal muscle FNDC5 expression and/or increase plasma irisin concentrations (102). Here, FNDC5 is linked to metabolic syndrome.